IL28B polymorphisms do not predict response to therapy in chronic hepatitis C with HCV genotype 5

Gut

Volumn 61, Issue 11, 2012, Pages 1640-1641

  Antaki, Nabil ^a   Bibert, Stéphanie ^b   Kebbewar, Kamel ^a   Asaad, Fouad ^c   Baroudi, Osama ^d   Alideeb, Sawsan ^d   Hadad, Milad ^e   Abboud, Dirar ^a   Sabah, Houda ^d   Bochud, Pierre Yves ^b   Negro, Francesco ^f  

^a Saint Louis Hospital   (Syrian Arab Republic)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

^c Squelbiye National Hospital   (Syrian Arab Republic)

^d Damascus Hospital   (Syrian Arab Republic)

^e Ibn Nafis Hospital   (Syrian Arab Republic)

^f University Hospitals   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GENOMIC DNA; INTERLEUKIN 28B; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

BODY MASS; DISEASE ASSOCIATION; GENE; GENE FREQUENCY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 5; HUMAN; IL28B GENE; LETTER; LIVER BIOPSY; LIVER FIBROSIS; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PREDICTIVE VALIDITY; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; SUSTAINED VIROLOGICAL RESPONSE; SYRIAN ARAB REPUBLIC; TREATMENT RESPONSE; VIRUS LOAD;

ANTIVIRAL AGENTS; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84866993157     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-302019     Document Type: Letter

References (4)

1. Hayes CN, Kobayashi M, Akuta N, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. Gut 2011;60:261-7.
2. Clark PJ, Thompson AJ, McHutchison JG. IL28B genomic-based treatment paradigms for patients with chronic hepatitis c infection: the future of personalized HCV therapies. Am J Gastroenterol 2011;106:38-45.
3. Antaki N, Craxi A, Kamal S, et al. The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report. Liver Int 2010;30:342-55.
4. European Association for the Study of the Liver. EASL clinical Practice guidelines: management of hepatitis C virus infection. J Hepatol 2011;55:245-64.